Lorem ipsum dolor sit amet, consectetur adipiscing elit. Mauris semper porttitor tortor ut condimentum. Sed non pretium libero. Cras magna ante, sollicitudin in pellentesque eget, porta eu quam.
In pretium enim nec neque auctor, non mollis nunc maximus. Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Nulla a volutpat arcu, id varius lacus. Morbi non sodales odio, nec posuere nisl. Phasellus vulputate nunc id quam hendrerit, sit amet fringilla magna consequat.
The 2013 NICE guidelines for familial breast cancer are available here.
UKCGG has worked with the British Society of Gastroenterology and the Association of Coloproctologists of Great Britain and Ireland to produce new guidance on the screening and management of patients with an increased genetic predisposition to colorectal cancer.
Unfortunately there is not enough evidence to review regarding the use of aspirin in patients at high risk of colorectal cancer outside of the context of Lynch Syndrome. However, given the evidence supporting use of aspirin in Lynch Syndrome and the growing body of evidence with respect to reduction in colorectal cancer risk with aspirin in the general population, we advise that patients at high risk of developing colorectal cancer on the basis of their family history should see their GP to discuss the risks and benefits of low dose (75-150mg) daily aspirin for bowel cancer risk reduction.
The 2013 European Guidelines for Lynch Syndrome management have been superseded by the recently published UK gene-specific guidelines. The full original text for the 2013 guidelines produced by the Mallorca group can be accessed here.
Peer-reviewed published guidelines from national and international expert groups are available at the links here below. For additional UKCGG guidelines and leaflets, please click here.
The 2013 NICE guidelines for familial breast cancer are available here.
CGG have produced information leaflets that may be used for women at increased risk of breast cancer who are considering the use of chemoprevention.
The leaflets are available from here. Please note that any use of the leaflets is the responsibility of the health professional/person concerned.
UKCGG has worked with the British Society of Gastroenterology and the Association of Coloproctologists of Great Britain and Ireland to produce new guidance on the screening and management of patients with an increased genetic predisposition to colorectal cancer.
Unfortunately there is not enough evidence to review regarding the use of aspirin in patients at high risk of colorectal cancer outside of the context of Lynch Syndrome. However, given the evidence supporting use of aspirin in Lynch Syndrome and the growing body of evidence with respect to reduction in colorectal cancer risk with aspirin in the general population, we advise that patients at high risk of developing colorectal cancer on the basis of their family history should see their GP to discuss the risks and benefits of low dose (75-150mg) daily aspirin for bowel cancer risk reduction.
The 2013 European Guidelines for Lynch Syndrome management have been superseded by the recently published UK gene specific guidelines. The full original full text for the 2013 guidelines produced by the Mallorca group can be accessed here.
Loading...